Literature DB >> 3500717

Inhibition of mitochondrial respiration by analogs of 4-phenylpyridine and 1-methyl-4-phenylpyridinium cation (MPP+), the neurotoxic metabolite of MPTP.

C L Hoppel1, D Grinblatt, H C Kwok, P K Arora, M P Singh, L M Sayre, D Greenblatt.   

Abstract

In order to clarify the structural requirements associated with the inhibition of mitochondrial respiration by MPP+, the neurotoxic metabolites of the Parkinsonian agent MPTP, ten sets of pyridine/N-methylpyridinium pairs and a few miscellaneous compounds were evaluated on rat liver intact mitochondria (Mw) and on submitochondrial particles (SMP). The pyridinium partners were much more potent inhibitors on Mw than on SMP, indicating that they are concentrated inside mitochondria by the energy-dependent process previously reported for MPP+, probably as a consequence of non-specific passive transport across the mitochondrial inner membrane in response to the transmembrane potential. In the SMP assay, the neutral pyridines were stronger inhibitors than were the pyridinium cations, and the inhibitory potency varied little with structural changes. The N-methylated forms of beta-carbolines may act as endogenous MPP+-like agents.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3500717     DOI: 10.1016/0006-291x(87)90931-4

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

Review 1.  MPTP as a mitochondrial neurotoxic model of Parkinson's disease.

Authors:  Serge Przedborski; Kim Tieu; Celine Perier; Miquel Vila
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

2.  [3H]dihydrorotenone binding to NADH: ubiquinone reductase (complex I) of the electron transport chain: an autoradiographic study.

Authors:  D S Higgins; J T Greenamyre
Journal:  J Neurosci       Date:  1996-06-15       Impact factor: 6.167

3.  Inhibition of complex I by hydrophobic analogues of N-methyl-4-phenylpyridinium (MPP+) and the use of an ion-selective electrode to measure their accumulation by mitochondria and electron-transport particles.

Authors:  M P Murphy; M J Krueger; S O Sablin; R R Ramsay; T P Singer
Journal:  Biochem J       Date:  1995-03-01       Impact factor: 3.857

4.  Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine.

Authors:  R Albores; E J Neafsey; G Drucker; J Z Fields; M A Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 5.  Early Parkinson's disease: what is the best approach to treatment.

Authors:  A H Hristova; W C Koller
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

6.  Role of lipoamide dehydrogenase and metallothionein on 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity.

Authors:  Muralikrishnan Dhanasekaran; Christian B Albano; Lori Pellet; Senthilkumar S Karuppagounder; Subramaniam Uthayathas; Vishnu Suppiramaniam; Holly Brown-Borg; Manuchair Ebadi
Journal:  Neurochem Res       Date:  2007-09-01       Impact factor: 3.996

Review 7.  alpha-Synuclein: a therapeutic target for Parkinson's disease?

Authors:  Kathleen A Maguire-Zeiss
Journal:  Pharmacol Res       Date:  2008-09-16       Impact factor: 7.658

8.  Uptake and accumulation of 1-methyl-4-phenylpyridinium by rat liver mitochondria measured using an ion-selective electrode.

Authors:  G P Davey; K F Tipton; M P Murphy
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

Review 9.  Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease.

Authors:  Dominik Haddad; Ken Nakamura
Journal:  FEBS Lett       Date:  2015-10-23       Impact factor: 4.124

10.  Mitochondrial dysfunction in Parkinson's disease.

Authors:  P C Keane; M Kurzawa; P G Blain; C M Morris
Journal:  Parkinsons Dis       Date:  2011-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.